Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 153 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... January 7, 2021 New on NCI’s Websites for October 2019 October 3, 2019 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 Giving Myself the Most Time and Best Chance at Beating Cancer:... October 10, 2023 Load more HOT NEWS Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy A Daily Survival Kit for Serious Illness
